Cancer Treatment Today

Uterine clear cell carcinoma (UCC) and uterine papillary serous carcinoma (UPSC) are rare entities that differ in clinical behavior from endometrial adenocarcinoma. Compared with endometrioid adenocarcinoma, they more often metastasize early and more commonly in the upper abdomen including the omentum.Rosenberg showed that intensive treatment produces better results.In a 2023 study, researchers found that adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy improved overall survival. And another 2023 studyTrusted Source found that the immune therapy drug dostarlimab (Jemperli) showed similar positive results when added to chemotherapy treatment.

Eskander et al published a phase III trial using carboplatin, paclitaxel and permbrolizumab or placebo that favored the 3 drug combination arm. In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
BENGT LINDAHL, JAN PERSSON, JONAS RANSTAM, ROGER WILLÉN, Long-term Survival in Uterine Clear Cell Carcinoma and Uterine Papillary Serous Carcinoma Anticancer Research Sep 2010, 30 (9) 3727-3730;

Rosenberg P, Blom R, Högberg T, Simonsen E: Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 51: 311-315, 1993.

Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-215

Ramez N. Eskander, M.D., Michael W. Sill, Ph.D., Lindsey Beffa, M.D., Richard G. Moore, M.D. https://orcid.org/0000-0001-5598-5263, Joanie M. Hope, M.D., Fernanda B. Musa, M.D., Robert Mannel, M.D., +19, and Carol Aghajanian, M.D, Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med 2023;388:2159-2170.